Killing of Borrelia burgdorferi by Antibody Elicited by OspA Vaccine Is Inefficient in the Absence of Complement
A Lyme disease vaccine, based on the Borrelia burgdorferi lipoprotein OspA, has recently undergone phase III trials in humans. The results of one of these trials indicate that vaccine efficacy positively correlates with anti-OspA antibody titer. Spirochete killing within the tick vector midgut, upon...
Uloženo v:
| Vydáno v: | Infect Immun |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Society for Microbiology (ASM)
1999
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC96334/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/9864253/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/iai.67.1.443-445.1999 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|